ELAB saw its Momentum Indicator move below the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 45 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ELAB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ELAB just turned positive on September 21, 2026. Looking at past instances where ELAB's MACD turned positive, the stock continued to rise in 10 of 14 cases over the following month. The odds of a continued upward trend are 71%.
Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAB advanced for three days, in 74 of 89 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ELAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.231) is normal, around the industry mean (26.782). P/E Ratio (0.005) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.250) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ELAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LPCN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 15, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 36 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LPCN as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
LPCN moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LPCN crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for LPCN entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where LPCN advanced for three days, in 213 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
LPCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.792) is normal, around the industry mean (26.782). P/E Ratio (7.686) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (9.302) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LPCN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 84 | |
P/E GROWTH RATING 1..100 | 95 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ELAB | LPCN | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 71% | 3 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Advances ODDS (%) | 20 days ago 83% | 11 days ago 82% |
| Declines ODDS (%) | 4 days ago 90% | 1 day ago 86% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELAB’s FA Score shows that 1 FA rating(s) are green while LPCN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELAB’s TA Score shows that 4 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).
ELAB (@Biotechnology) experienced а -9.48% price change this week, while LPCN (@Biotechnology) price change was -9.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
LPCN is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with LPCN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then LPCN could also see price increases.
| Ticker / NAME | Correlation To ELAB | 1D Price Change % | ||
|---|---|---|---|---|
| ELAB | 100% | -7.51% | ||
| LPCN - ELAB | 42% Loosely correlated | -7.14% | ||
| LXRX - ELAB | 25% Poorly correlated | -7.88% | ||
| HURA - ELAB | 25% Poorly correlated | -3.83% | ||
| ERNA - ELAB | 24% Poorly correlated | -3.69% | ||
| MTNB - ELAB | 24% Poorly correlated | -2.07% | ||
More | ||||
A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.
| Ticker / NAME | Correlation To LPCN | 1D Price Change % | ||
|---|---|---|---|---|
| LPCN | 100% | -7.14% | ||
| SPRY - LPCN | 63% Loosely correlated | -1.23% | ||
| HYFT - LPCN | 43% Loosely correlated | -6.43% | ||
| ELAB - LPCN | 41% Loosely correlated | -7.51% | ||
| INO - LPCN | 41% Loosely correlated | -4.80% | ||
| ZNTL - LPCN | 36% Loosely correlated | -4.91% | ||
More | ||||